2020 US Medicinal Products

Financial Strength Rankings using Artificial Intelligence

Top rated13 of 52
Best rating554 %
Worst rating-2,048 %
New companies8
Negative Economic Capital Ratio26 of 52

CAT9 Group Inc. climbed 20 positions from 40 to 20 due it’s excellent Net Income. MARIMED INC. lost 36 positions from 9 to 45 due it’s bad Assets. Cronos Group Inc. entered the 2020 ranking at rank 1, making it the best newcomer.

Revenues37.3 B
Assets60.1 B
Expenses36.0 B
Stockholders Equity24.6 B
Unprofitable companies33 of 52

1. Cronos Group Inc.

553.87%

4. NEOGEN CORP

250.05%

6. INNOSPEC INC.

196.36%

7. FMC CORP

152.85%

8. BALCHEM CORP

145.12%

9. Livent Corp.

136.83%

11. MYRIAD GENETICS INC

119.17%

12. GULF RESOURCES INC.

118.14%

14. IMMUCELL CORP DE

109.44%

15. HESKA CORP

98.11%

16. MANNATECH INC

85.35%

17. Huntsman CORP

78.15%

19. Ingevity Corp

72.24%

20. CAT9 Group Inc.

69.45%

21. Ecovyst Inc.

68.05%

23. OLIN Corp

28.88%

24. W R GRACE & CO

26.21%

25. Chemours Co

14.32%

26. CYANOTECH CORP

8.12%

28. Tilray Brands Inc.

-27.38%

32. BIOMERICA INC

-164.61%

34. IMMUNOMEDICS INC

-215.00%

35. Oncocyte Corp

-233.75%

36. Target Group Inc.

-279.94%

37. ARCA biopharma Inc.

-293.51%

38. ChromaDex Corp.

-359.80%

42. Stem Holdings Inc.

-475.26%

45. MARIMED INC.

-557.25%

50. TAURIGA SCIENCES INC.

-1177.33%

52. QUANTA INC

-2048.46%

United States Ratings

German Insurance Ratings